Shopping Cart
- Remove All
Your shopping cart is currently empty
BRD0209
Catalog No. T26894Cas No. 1597439-87-6
Alias BRD-0209, BRD 0209
BRD0209 is a highly selective and potent GSK3 inhibitor.
BRD0209
Catalog No. T26894Alias BRD-0209, BRD 0209Cas No. 1597439-87-6
BRD0209 is a highly selective and potent GSK3 inhibitor.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $55 | In Stock | |
| 5 mg | $129 | In Stock | |
| 10 mg | $208 | In Stock | |
| 25 mg | $377 | In Stock | |
| 50 mg | $537 | In Stock | |
| 100 mg | $732 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "BRD0209"
4-Chloro-2'-bromoacetophenone
T8908536-38-9
4-Chloro-2'-bromoacetophenone against glycogen synthase kinase-3 (GSK-3beta).
- $30
Size
QTY
CHIR-99021
Cited
Laduviglusib, CT99021, CHIR-99021
T2310252917-06-9
CHIR-99021 (CT99021) is an activator of the Wnt/β-catenin signaling pathway and a GSK-3α/β inhibitor (IC50=10/6.7 nM) with selective and oral activity.CHIR-99021 induces cellular autophagy, which enhances self-renewal in mouse and human embryonic stem cells.
- $36
Size
QTY
CitedCromolyn sodium
Sodium cromoglycate, FPL-670, FPL 670 (Cromolyn) Disodium, Disodium Cromoglycate
T126015826-37-6
Cromolyn sodium (FPL-670) is a chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells.
- $48
Size
QTY
GSK-3 Inhibitor 5
4-Cyanophenacyl bromide
T7755420099-89-2
GSK-3 Inhibitor 5 (4-Cyanophenacyl bromide) is a ketone derivative that is used as an intermediate in pharmaceuticals and organic synthesis, and inhibits glycogen synthase kinase 3 (GSK-3).
- $29
Size
QTY
GSK 3 Inhibitor IX Cited
MLS 2052, GSK 3 IX, BIO, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, 6-BIO
T1917667463-62-9
GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity with IC50 values of 5 nM/320 nM/83 nM, respectively.
- $37
Size
QTY
CitedAT7519 Cited
T6205844442-38-2
AT7519 is a CDK1/2/4/6/9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7.
- $52
Size
QTY
CitedSNS-032 Cited
SNS032, BMS-387032
T6049345627-80-7
SNS-032 (BMS-387032) is a selective inhibitor of CDK2 (IC50: 48 nM), exhibiting 10- and 20-fold selectivity over CDK1 and CDK4, respectively. It is also sensitive to CDK7 (IC50: 62 nM) and CDK9 (IC50: 4 nM), with no effect on CDK6.
- $43
Size
QTY
CitedMeBIO
T21966667463-95-8
MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.
- $33
Size
QTY
5-Bromoindole
T747310075-50-0
5-bromoindole is a potential inhibitor of glycogen synthase kinase 3 (GSK-3)and an important pharmaceutical chemical intermediate
- $29
Size
QTY
1-Azakenpaullone
azakenpaullone
T6358676596-65-9
1-Azakenpaullone (azakenpaullone) is a potent and selective GSK-3β inhibitor with IC50 of 18 nM, >100-fold selectivity over CDK1/cyclin B and CDK5/p25.
- $72
Size
QTY
PHA-767491 Cited
PHA767491, PHA 767491, CAY10572
T6206845714-00-3
PHA-767491 (CAY10572) is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.
- $30
Size
QTY
CitedCHIR-99021 HCl Cited
Laduviglusib HCl, CT99021 HCl
T2310L1797989-42-4
CHIR-99021 HCl (Laduviglusib HCl) is a highly potent and selective inhibitor of GSK-3α/β, with IC50 values of 10 nM and 6.7 nM respectively. It demonstrates remarkable selectivity for GSK-3, with over 500-fold selectivity over CDC2, ERK2, and other protein kinases. Additionally, CHIR-99021 HCl serves as a robust activator of the Wnt/β-catenin signaling pathway. Moreover, it exhibits the ability to enhance self-renewal in both mouse and human embryonic stem cells. Furthermore, CHIR-99021 HCl induces autophagy [1] [2] [3].
- $30
Size
QTY
CitedSelect Batch
Purity:99.75%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | BRD0209 is a highly selective and potent GSK3 inhibitor. |
| Targets&IC50 | GSK-3α:19 nM, GSK-3β:5 nM |
| In vitro | BRD0209 showed concentration-dependent inhibition of Tau with cellular EC50s of 1.76 μM, respectively, in SH-SY5Y cells using ELISA. Treatment of SH-SY5Y cells with BRD0209 (10 μM) significantly inhibited GSK3 kinase activity within 30 min, as seen in the decrease in phospho-CRMP2 and phospho-β-catenin. BRD0209 is also a reversible ATP-competitive inhibitor with fast-off kinetics (Ki = 4.2 nM, respectively).BRD0209 treatment caused a dramatic decrease in autophosphorylation at Tyr279 (pGSK3α) and Tyr216 (pGSK3β) with longer exposure (24 h) [1]. |
| Alias | BRD-0209, BRD 0209 |
| Molecular Weight | 347.45 |
| Formula | C22H25N3O |
| Cas No. | 1597439-87-6 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
| Solubility Information | DMSO: 3.47 mg/mL (10 mM), Sonication is recommended.  | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy BRD0209 | purchase BRD0209 | BRD0209 cost | order BRD0209 | BRD0209 chemical structure | BRD0209 in vitro | BRD0209 formula | BRD0209 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.